Lin Patrick 4

What Happened

• Lin Patrick, Chief Business & Strategy Officer at Processa Pharmaceuticals (PCSA), made an open-market purchase of 2,106 shares on June 30, 2026. The shares were bought at $1.93 each for a total cash outlay of approximately $4,065. This is a straightforward purchase (transaction code P), which is generally considered more informative than routine sales.

Key Details

• Transaction date and price: 2026-06-30, 2,106 shares at $1.93 per share (total ≈ $4,065).
• Filing date: 2026-07-01 (the Form 4 was filed the next day and appears timely under the two-business-day requirement).
• Shares owned after transaction: Not specified in the provided transaction details.
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes were indicated in the supplied data.

Context

• Small-dollar insider purchases like this (≈ $4K) are factual signals of personal buying but are modest in size and may not strongly change market view on their own. Purchases are often noted by investors because they can indicate confidence, but filings do not state the insider’s motivation.